Durbin's Supplement Listing Act Returns — This Time With Industry Support
By Himiyer.com — March 23, 2026
Background
U.S. Senate Majority Whip Richard Durbin (D-IL) introduced the Dietary Supplement Listing Act of 2026 in January, reintroducing legislation he has championed for years. The core argument: the FDA currently has no comprehensive list of what supplement products exist on the market, hampering its ability to oversee a category that has grown from roughly 4,000 products in 1994 to an estimated 80,000–100,000 today.
What the Bill Requires
Under the proposed legislation, supplement manufacturers would be required to submit the following to the FDA before or upon placing a product on the market:
- Product name and brand
- Full ingredient list
- An electronic copy of the label
- Allergen statements
- Any health, structure/function, or other claims made on the label
That data would be compiled into a publicly accessible electronic database, updated on a rolling basis. Proprietary blend ingredient details would have to be disclosed to the FDA but would remain confidential from the public. Products failing to comply would be considered misbranded under federal law.
Who Supports It
The Council for Responsible Nutrition (CRN) — which opposed the 2024 version of the bill — issued a statement supporting the 2026 version. CRN president Steve Mister cited the removal of provisions it had considered overreaching, particularly the earlier requirement that all marketing claims made on company websites be included in the registration, regardless of whether they appeared on product labels. "Consumers deserve to know what products are on the market and what they contain," Mister said.
Who Opposes It
The Natural Products Association (NPA) rejected the bill, arguing it adds costly regulatory overhead and would disproportionately burden smaller supplement companies. The NPA contends the legislation does little to stop the bad actors it nominally targets, since companies selling illegal or adulterated products are unlikely to comply with a voluntary registration regime in the first place. The United Natural Products Alliance (UNPA) has raised similar concerns.
Legislative Outlook
The bill faces a divided industry and an uncertain Senate calendar. Earlier companion versions have stalled at the committee level. However, the shift in CRN's position may improve its chances of advancing further in 2026 than prior versions managed.
